109 related articles for article (PubMed ID: 16231850)
1. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials.
Moser EC; Noordijk EM; Carde P; Tirelli U; Baars JW; Thomas J; Bron D; Meerwaldt JH; van Glabbeke M; Raemaekers JM; Kluin-Nelemans HC
Clin Lymphoma Myeloma; 2005 Sep; 6(2):122-30. PubMed ID: 16231850
[TBL] [Abstract][Full Text] [Related]
2. Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.
Moser EC; Noordijk EM; van Leeuwen FE; Baars JW; Thomas J; Carde P; Meerwaldt JH; van Glabbeke M; Kluin-Nelemans HC
Haematologica; 2006 Nov; 91(11):1481-8. PubMed ID: 17043014
[TBL] [Abstract][Full Text] [Related]
3. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
4. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
5. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma.
Bokemeyer C; Schmoll HJ; van Rhee J; Kuczyk M; Schuppert F; Poliwoda H
Ann Hematol; 1994 Mar; 68(3):105-10. PubMed ID: 8167175
[TBL] [Abstract][Full Text] [Related]
6. High incidence of secondary myelodysplastic syndromes following PROMACE-MOPP and involved field radiotherapy for localized gastric non-Hodgkin's lymphomas.
Corti C; Theodore C; Bayle C; Rougier P; Nasr F; Cosset JM; Girinsky T; Hayat M; Ribrag V
Hematol Oncol; 1996 Dec; 14(4):159-63. PubMed ID: 9267461
[TBL] [Abstract][Full Text] [Related]
7. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
8. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
10. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
11. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
13. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
14. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
15. [Second neoplasms as a late complication of the treatment of Hodgkin's disease].
Morales MD; González FA; Villegas A; del Potro E; Díaz Mediavilla J; Martínez R; Alvarez A; Colomé JA
Sangre (Barc); 1992 Dec; 37(6):429-33. PubMed ID: 1293793
[TBL] [Abstract][Full Text] [Related]
16. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.
Swerdlow AJ; Schoemaker MJ; Allerton R; Horwich A; Barber JA; Cunningham D; Lister TA; Rohatiner AZ; Vaughan Hudson G; Williams MV; Linch DC
J Clin Oncol; 2001 Mar; 19(6):1610-8. PubMed ID: 11250989
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
19. Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research and Treatment of Cancer.
Carde P; Hayat M; Cosset JM; Somers R; Burgers JM; Sizoo W; Meerwaldt JH; Hagenbeek A; Monconduit M; van der Schueren E
NCI Monogr; 1988; (6):303-10. PubMed ID: 3352775
[TBL] [Abstract][Full Text] [Related]
20. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
